Dementia Trials Australia

DTAus

Dementia Trials Australia (DTAus) is the key body in promoting, facilitating and coordinating both commercially-sponsored and investigator-initiated dementia and cognition trials in Australia. The network provides an effective communication channel between local clinicians and study sponsors and has played an increasingly important role in attracting studies throughout Australasia. A central part of what the DTAus does is to assist sponsors in determining the feasibility of conducting new studies in our region and to set appropriate recruitment forecasts. We do this by reviewing the study protocol, budget and study logistics, and number of Australian sites required in the context of current competing studies. This process allows the early identification of potential problems with local ethics committees and draws on an intimate understanding of local capabilities.

Aims

  • To give a thorough review of study protocols, budgets, study logistics and a guidance on the number of Australian sites required for a study.
  • To help research organisations identify centres appropriate for any proposed new trial.
  • To ensure a coordinated strategy for involvement of the Australasian region in International clinical cognitive disorder research trials.

  • To assist sponsors in determining feasibility when conducting new studies within the Australasian region.

     

  • To identify the potential problems of local ethics committees and grasp an understanding of their local capabilities.
  • To establish a forum for the exchange of communication of information with local clinicians and study sponsors.

DTAus – Alzheimer’s beyond COVID-19

DTAus’s Activities

Current Trials

Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial

Status: Recruiting

Sponsor: Australia Shineway Technology Pty Ltd

Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO).

Status: Active

Sponsor: Biogen

A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer’s

Status: Recruiting

Sponsor: ImmuneBio

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer’s Disease.

Status: Recruiting

Sponsor: Cognition Therapeutics

COVID-19 Updates

Coronavirus Disease 2019 (COVID-19) is a disease caused by a new form of coronavirus which developed into a pandemic in early 2020 bringing new challenges for health care workers and research staff.

As an organisation our number one priority is the health and safety of site staff, our clinical trial participants, the broader community and trial integrity. The COVID -19 situation is continually changing and research sites across Australia have succeeded in the implementation of contingency measures to manage study disruption.  Australian sites are actively managing research activities including trial participation according to relevant State and National guidelines.

DTAus would like to highlight that the highly qualified clinical sites in Australia are currently undertaking clinical trials and the safety and well-being of clinical trial participants, visitors, clinical staff and quality of trials will always be paramount.  DTAus are committed to supporting the vital work undertaken by our clinical trial sites with clinical trials continuing to take place across Australia.

Resources and Updates about COVID-19 pandemic.

Past Events

AC4R – Annual Scientific Meeting: “Alzheimer’s Trials: Beyond Amyloid” 2019  Conference Slides

Affiliations

Menu